Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
Author Information
Author(s): Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra
Primary Institution: Niguarda Ca’ Granda Hospital, Milano, Italy
Hypothesis
The use of nucleoside analogs and alkylating agents in treating CLL and WM may increase the risk of developing secondary myeloid neoplasms.
Conclusion
The study highlights the increased risk of secondary myeloid neoplasms in patients with CLL and WM due to therapy-related factors.
Supporting Evidence
- Up to 10% of patients treated for indolent non-Hodgkin’s lymphoma develop MDS or AML within a decade of primary therapy.
- Secondary MDS/AML are frequently reported complications in patients treated with alkylating agents and nucleoside analogs.
- Patients with WM have a documented increased risk of second cancers, particularly secondary MDS/AML.
Takeaway
Patients with certain blood cancers might get more sick from their treatment later on, which can lead to new types of blood cancers.
Methodology
The review summarizes published studies on the incidence of secondary MDS and AML in CLL and WM patients and discusses the role of chemotherapeutic agents in leukemogenesis.
Potential Biases
Potential biases may arise from retrospective study designs and the influence of multiple lines of therapy.
Limitations
The impact of specific therapeutic agents on the risk of secondary MDS/AML is not definitively clarified due to confounding factors.
Participant Demographics
The study includes patients with Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia, with varying treatment histories.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website